A sponsor-reported trial result
Merck and Moderna reported that INTerpath-001 met its recurrence-free and distant-metastasis-free survival endpoints. The study compared investigational intismeran plus pembrolizumab with pembrolizumab alone in resected melanoma. A topline sponsor announcement is distinct from a full results presentation or regulatory approval. [1]
The separately documented AI component
Moderna describes AI algorithms selecting neoantigens from tumor and blood sequencing data for its individualized mRNA therapy. That design process explains the program’s AI relevance. The clinical comparison tests a treatment regimen, rather than isolating the effect of the selection algorithm. [3][1]
Sources
- Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma
Merck · Aug 19, 2026
- Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial
STAT · Aug 19, 2026
- Advancing the Fight Against Cancer through mRNA & AI
Moderna · Dec 19, 2023